Trials / Completed
CompletedNCT02072928
Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence From Neurogenic Detrusor Overactivity in Belgium
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 55 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the impact of BOTOX® treatment on anticholinergic drug use in patients with urinary incontinence from Neurogenic Detrusor Overactivity (NDO) due to spinal injury or Multiple Sclerosis (MS) who are prescribed BOTOX® as standard of care in clinical practice.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | botulinum toxin Type A | botulinum toxin Type A (BOTOX®) prescribed as standard of care in clinical practice. |
Timeline
- Start date
- 2014-01-28
- Primary completion
- 2015-09-30
- Completion
- 2015-09-30
- First posted
- 2014-02-27
- Last updated
- 2017-12-15
- Results posted
- 2017-12-15
Locations
6 sites across 1 country: Belgium
Source: ClinicalTrials.gov record NCT02072928. Inclusion in this directory is not an endorsement.